Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

LY-2090314

Generic Name: LY-2090314

Drug Type: Small Molecule

Chemical Formula: C_₂₈H_₂₅FN_₆O_₃

CAS Number: 603288-22-8

Unique Ingredient Identifier: 822M3GYM67

Overview

Ly2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.

Background

Ly2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Phase 1

Terminated

Posted: 2012/07/02

Sponsor:Eli Lilly and Compan...

ID:NCT01632306

A Study of LY2090314 in Patients With Advanced or Metastatic Cancer

Phase 1

Completed

Posted: 2011/02/01

Sponsor:Eli Lilly and Compan...

ID:NCT01287520

A Study in Participants With Acute Leukemia

Phase 2

Completed

Posted: 2010/10/05

Sponsor:Eli Lilly and Compan...

ID:NCT01214603

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Overcoming Osimertinib Resistance in EGFR-Mutant NSCLC Through GSK-3 Inhibition

5 years ago

A study reveals that Glycogen Synthase Kinase-3 (GSK-3) inhibition can overcome epithelial-mesenchymal transition (EMT)-mediated resistance to osimertinib in EGFR-mutant non-small cell lung cancer (NSCLC), offering a potential therapeutic strategy for patients with acquired resistance to EGFR-TKIs.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy